Improving the morbidity of anorectal injury from pelvic radiotherapy

被引:9
作者
Abbasakoor, F [1 ]
Vaizey, CJ [1 ]
Boulos, PB [1 ]
机构
[1] UCL Royal Free & Univ Coll Med Sch, Dept Surg, Colorectal Surg Unit, London W1W 7EJ, England
关键词
pelvic radiotherapy; radioprotection; anorectal; radiation injury;
D O I
10.1111/j.1463-1318.2005.00851.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective Radiation anorectal injury due to pelvic radiotherapy for non intestinal cancer is a significant cause of morbidity which may limit the treatment dose required. Conservative treatment options are of limited value and surgery is reserved only for the most severe complications. This review addresses radioprotection of the anorectum and aims to increase awareness amongst surgeons of the strategies that have been in practice in order to minimize the side-effects of radiotherapy while preserving its therapeutic efficacy. Methods This review is based on a literature search (Medline and NLM PubMed) with manual cross-referencing of all articles related to anorectal radiation injury. Results Optimization of radiation dose, the use of radioprotective agents and improvement in radiation delivery are the main areas of development. There are few data on the potential of altered fractionation schedules in reducing anorectal injury. A few phase I and II studies suggest that the pharmacological agents amifostine and misoprostol could be beneficial in limiting radiation damage but larger phase III studies are awaited. Conclusion The introduction of 3-dimensional conformal radiation therapy and intensity modulated radiation therapy has been the most significant advance in reducing radiation morbidity.
引用
收藏
页码:2 / 10
页数:9
相关论文
共 80 条
[1]  
ABBASAKOOR F, 2004, COLORECTAL DIS, V6, P61
[2]  
Ang KK, 2004, PRINCIPLES PRACTICE, P337
[3]   BB-10010, an analog of macrophage inflammatory protein-1α, protects murine small intestine against radiation [J].
Arango, D ;
Ettarh, RR ;
Holden, G ;
Moriarty, M ;
Brennan, PC .
DIGESTIVE DISEASES AND SCIENCES, 2001, 46 (12) :2608-2614
[4]  
Arango D, 1999, SCAND J GASTROENTERO, V34, P68
[5]   Dose-effect relationship of BB-10010/MIP-1 alpha on proliferation in murine small intestinal epithelium: Single and double administration protocols [J].
Arango, D ;
Ettarh, RR ;
Brennan, PC .
DIGESTIVE DISEASES AND SCIENCES, 2000, 45 (12) :2306-2312
[6]   Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: Results of a randomized trial [J].
Athanassiou, H ;
Antonadou, D ;
Coliarakis, N ;
Kouveli, A ;
Synodinou, M ;
Paraskevaidis, M ;
Sarris, G ;
Georgakopoulos, GR ;
Panousaki, K ;
Karageorgis, P ;
Throuvalas, N .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (04) :1154-1160
[7]  
Babb RR, 1996, AM J GASTROENTEROL, V91, P1309
[8]   Is tomotherapy the future of IMRT? [J].
Beavis, AW .
BRITISH JOURNAL OF RADIOLOGY, 2004, 77 (916) :285-295
[9]   Intrarectal application of amifostine for the prevention of radiation-induced rectal injury [J].
Ben-Josef, E ;
Han, S ;
Tobi, M ;
Vargas, BJ ;
Stamos, B ;
Kelly, L ;
Biggar, S ;
Kaplan, I .
SEMINARS IN RADIATION ONCOLOGY, 2002, 12 (01) :81-85
[10]  
Beyzadeoglu M, 1997, Radiat Med, V15, P1